dry mouth on semaglutide GLP-1 Medications and Mouth: Managing New Side Effects Ozempic and other GLP-1s may

Using rodent models of obesity and metabolic dysfunction, the research group demonstrated that the triple-agonist approach produced meaningful reductions in body weight and improved glycaemic parameters compared to both placebo and comparator compounds targeting fewer receptors

Some patients with obesity and metabolic syndromethe population commonly prescribed tirzepatidemay have underlying inflammatory conditions that coincidentally become apparent during treatment

Ingredients The active ingredient is semaglutide, a GLP-1 receptor agonist that closely mimics a natural gut hormone your body releases after eating

It is also being studied for its potential to slow the progression of neurodegenerative diseases like Alzheimer's